Clinical Trial Update: Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating NVG-2089 for safety, tolerability, and efficacy in immune thrombocytopenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• NVG-2089

Snippet

Sponsor: Nuvig Therapeutics, Inc. | Conditions: Immune Thrombocytopenia (ITP) | Phase 2 | Status: RECRUITING